Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Article CommentaryCommentary

A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency

Hongbin Yu and Donald Tweedie
Drug Metabolism and Disposition March 2013, 41 (3) 536-540; DOI: https://doi.org/10.1124/dmd.112.048892
Hongbin Yu
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald Tweedie
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 41 no. 3 536-540
DOI 
https://doi.org/10.1124/dmd.112.048892
PubMed 
23143892

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received September 7, 2012
  • Accepted November 9, 2012
  • Published online February 15, 2013.

Article Versions

  • Earlier version (November 9, 2012 - 11:46).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Hongbin Yu and
  2. Donald Tweedie
  1. Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut
  1. Address correspondence to:
    Hongbin Yu, Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877. E-mail: hongbin.yu{at}boehringer-ingelheim.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: November 2012 to January 2021

AbstractFullPdf
Nov 20124300147
Dec 2012117030
Jan 2013164052
Feb 201397219195
Mar 201384822112
Apr 20132802161
May 20131711250
Jun 20131121539
Jul 20131241342
Aug 201377923
Sep 20131151425
Oct 2013721832
Nov 201375416
Dec 201361922
Jan 201465611
Feb 20147738
Mar 2014651231
Apr 2014552625
May 2014582428
Jun 2014432226
Jul 2014293114
Aug 2014441319
Sep 2014351924
Oct 2014581328
Nov 2014591921
Dec 201421128
Jan 2015231711
Feb 2015201713
Mar 2015312225
Apr 2015312119
May 2015172225
Jun 2015273323
Jul 2015272119
Aug 201518146
Sep 201529810
Oct 2015391112
Nov 2015161412
Dec 2015201318
Jan 2016261919
Feb 201611139
Mar 201625719
Apr 2016282211
May 20162944
Jun 201616425
Jul 20165615
Aug 2016221629
Sep 2016101322
Oct 201643120
Nov 201622318
Dec 201641413
Jan 201712914
Feb 20172246
Mar 201712618
Apr 201701612
May 201711813
Jun 201711316
Jul 20173911
Aug 201711110
Sep 201711217
Oct 201731914
Nov 201716628
Dec 201731613
Jan 201872514
Feb 201834018
Mar 201822612
Apr 20181217
May 20180238
Jun 20181257
Jul 201822617
Aug 201802113
Sep 20180207
Oct 201812012
Nov 20181174
Dec 20182184
Jan 20192495
Feb 20191666
Mar 20192298
Apr 20193608
May 20195137
Jun 2019171314
Jul 201935613
Aug 20192279
Sep 20191764
Oct 20191254
Nov 20192121
Dec 20191862
Jan 20203094
Feb 20201465
Mar 202015145
Apr 20202224
May 20204921
Jun 20202113
Jul 20201233
Aug 20201059
Sep 20202785
Oct 20203865
Nov 20201132
Dec 20201246
Jan 202115135

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (3)
Drug Metabolism and Disposition
Vol. 41, Issue 3
1 Mar 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Article CommentaryCommentary

Metabolite Contribution to DDI: Levels and Potency

Hongbin Yu and Donald Tweedie
Drug Metabolism and Disposition March 1, 2013, 41 (3) 536-540; DOI: https://doi.org/10.1124/dmd.112.048892

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Article CommentaryCommentary

Metabolite Contribution to DDI: Levels and Potency

Hongbin Yu and Donald Tweedie
Drug Metabolism and Disposition March 1, 2013, 41 (3) 536-540; DOI: https://doi.org/10.1124/dmd.112.048892
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Proposed Strategy for Assessing the Contribution of Metabolites to DDI
    • Consideration of Clinically Relevant Levels and Inhibition Potency of Metabolites That Contribute to Enzyme Inhibition
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Reporting Data Analysis and Statistical Methods
  • Underestimation of d-Methylphenidate Bioavailability
  • Intracellular and Intraorgan Drug Concentrations
Show more Commentary

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics